Advances in the Treatment Options for dMMR/MSI-H Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors

/ Print /
| ShareMore
/ Text Size +
11/5/20 1:00 pm EST
Virtual Webinar
United States


This webinar is jointly provided by CancerNet, LLC. and Amedo, LLC.

cancernet Logo 2017                      amedcologo    

This activity is supported in part by an independent education grant from Merck Sharp & Dohme Corp.

Webinar Overview:

This activity will cover topics on the diagnosis, treatment, and management of patients with colorectal cancer. Upon completion of this activity, participants should be better able to:

  • Assess the results of MSI/dMMR testing to determine appropriate patient selection of colorectal cancer (CRC)
  • Formulate treatment plans for metastatic CRC using immune checkpoint inhibition, alone or in combination with other therapies
  • Apply evidence-based strategies to monitor, recognize and effectively manage potential adverse events associated with immune checkpoint inhibition

Target Audience

This activity is designed to meet the educational needs of gastroenterologists, medical oncologists, radiation oncologists, surgeons, physician assistants, nurse practitioners, nurses, and healthcare professionals involved in the treatment of colorectal cancer patients.

Date and Time:

This webinar will be held on:

  • Thursday, November 5, 2020 1:00 PM – 2:15 PM EST
  • Tuesday, November 17, 2020 1:00 PM – 2:15 PM EST


Axel Grothey, MD
Director, GI Cancer Center Research
West Cancer Center & Research Institute
Germantown TN

Michael A. Morse, MD, FACP, MHS
Professor of Medicine
Professor in the Department of Surgery
Duke Cancer Institute
Durham, NC



  • Physicians, Physician Assistants, Nurse Practitioners — maximum of 1.25 AMA PRA Category 1 Credit(s)
  • Nurses — 1.25 Nursing Contact Hours
  • All other health care professionals completing this course will be issued a statement of participation.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation

Physician Continuing Medical Education

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™ for physicians and 1.25 hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Planners and Managers

  • Kamatham A. Naidu, PhD (CancerNet, LLC), has no relevant financial relationships.
  • Brian Waggoner (CancerNet, LLC) has no relevant financial relationships to disclose.
  • Sheryl Morgan (Amedco) has no relevant financial relationships to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive CME/CE credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.

Certificates will be emailed to the participant.

Disclosure of Unlabeled Use

CancerNet and Amedco require that faculty participating in any CME/CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.


Amedco makes every effort to develop CME/CE activities that are scientifically based.

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME/CE questions, please contact: Amedco at:

For questions regarding the content, please contact: CancerNet at